Skip to Content
Global News Select

Boston Scientific Raises 2021 Guidance

By Dave Sebastian

 

Boston Scientific Corp. raised its outlook for 2021 and made projections for the second quarter as it reported higher first-quarter profit and sales.

The Marlborough, Mass.-based medical-products company on Wednesday said it sees full-year net sales growth of about 16% to 19%, or about 15% to 18% on an organic basis. In February, it guided for a sales growth of 13% to 19%, or 12% to 18% on an organic basis.

The company said it expects full-year earnings of 81 cents a share to 88 cents a share, or $1.53 a share to $1.60 a share on an adjusted basis. It previously guided for earnings of 72 cents a share to 82 cents a share, or $1.50 a share to $1.60 a share on an adjusted basis.

For the second quarter, Boston Scientific said it sees net sales growing about 46% to 50%, or about 44% to 48% on an organic basis. It expects earnings of 16 cents a share to 18 cents a share, or 36 cents a share to 38 cents a share on an adjusted basis.

Organic sales exclude the effect of foreign-currency fluctuations and the acquisition of Preventice Solutions Inc., with no prior period related net sales, as well as the intrauterine health franchise, which the company divested in the second quarter of 2020, and the specialty pharmaceuticals business, which the company divested in the first quarter of 2021.

Shares rose 2.8% in premarket trading.

 

Write to Dave Sebastian at dave.sebastian@wsj.com

 

(END) Dow Jones Newswires

April 28, 2021 07:08 ET (11:08 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.